GlassScriptPhysician profile
Howard A Pickett
NPI 1821069790
$7,643.51
in general payments reported to CMS, 2019-2025
40 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $534 · 2021: $997 · 2022: $1,231 · 2023: $1,778 · 2024: $1,383 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,598.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,466.54 | 2021-2025 | |
| Lilly USA, LLC | $740.08 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $561.29 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $553.67 | 2022-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $550.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $443.27 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $370.01 | 2020-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $367.86 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Mylan Specialty L.P. | $294.62 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $284.63 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $254.17 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.48 | 2020-2025 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.20 | 2020-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $115.15 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $113.96 | 2023-2025 | Gemtesa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Pickett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.